Lead by Dr. Vincent Fradel of Laval University and sponsored by the Fonds de la Recherche en Sante du Quebec, as well as the Prostate Cancer Canada Network, a trial, currently in the recruiting stage, is aiming to determine "whether marine omega-3 fatty acids and 5-alpha-reductase inhibitor are effective in the progression of prostate cancer for low-risk prostate cancer patients. Set at a duration of one year for each participant, the study emphasizes that along with pharamcological treatments, a healthy and balanced diet is also essential, particularly in reducing the intake of saturated and trans fatty acids.
To read more about this trial, click here.
No comments:
Post a Comment